secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001104659-26-023806
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio presents Phase 2 TibuSURE trial design at SSc World Congress; no data yet
--------------------------------------------------------------------------------

- Design of Phase 2 TibuSURE trial evaluating tibulizumab (dual IL-17A/BAFF inhibition) in diffuse cutaneous systemic sclerosis accepted for poster presentation.
- Trial enrolls ~80 adults, randomized 1:1 tibulizumab versus placebo for 24 weeks, then 28-week open-label extension.
- Primary endpoint is change in modified Rodnan Skin Score at Week 24; topline results expected first half 2027.
- No clinical efficacy or safety data will be presented; poster covers rationale and study design only.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465926023806/0001104659-26-023806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465926023806/tm268054d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-023806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer